Veeva Sys Inc - VEEV STOCK NEWS

Veeva Systems (NYSE: VEEV) announced that over 350 companies are leveraging its Veeva Vault RIM Suite applications to enhance regulatory processes. In the past year, more than 65 emerging biotechs adopted these solutions to improve submission planning and compliance with evolving regulations. Notable advancements include Active Dossier management, label change tracking, and non-eCTD electronic publishing. A top 20 pharma streamlined 19 million data points through the platform, reducing SOPs by 90%. The suite's new features aim to accelerate time to market for submissions.

Veeva Systems (NYSE: VEEV) will host a virtual financial analyst and investor day on November 3, 2022. The event starts at 9:00 a.m. PT and ends around 11:00 a.m. PT. Presentations will be broadcast live on the company's investor relations website, with an archived link available post-event. Interested participants can register online through the investor relations site. Veeva leads in cloud software for the life sciences sector, serving over 1,000 clients.

Veeva Systems (VEEV) announced two innovative Crossix solutions aimed at enhancing omnichannel marketing for life sciences companies. The HCP Trigger Data connects patient engagement data with healthcare professional visits, helping marketers prioritize outreach effectively. Meanwhile, Omnichannel Boost provides a unified view of HCP and patient engagement across various channels, optimizing marketing performance. These tools aim to deliver actionable insights that enhance patient outcomes and improve marketing strategies, leveraging data covering over 300 million lives in the U.S.

Veeva Systems (NYSE: VEEV) announced that Batavia Biosciences has selected its Veeva Vault Quality Suite to enhance global quality assurance (QA). The cloud-based platform will streamline QA processes, facilitating real-time insights for better compliance and inspection readiness. Batavia, a Dutch CDMO specializing in viral vaccines, aims to optimize QA management through centralized documentation and training. Veeva's solutions will improve collaboration, reactiveness to quality events, and scalability of QA oversight across operations.

Veeva Systems (NYSE: VEEV) announced the upcoming Veeva R&D and Quality Summit on October 19-20 in Boston, featuring keynote speakers from major industry players like AbbVie, AstraZeneca, and GSK. This event will gather over 2,000 professionals and include more than 100 sessions focused on enhancing the efficiency of clinical trials and regulatory operations. Attendees will explore strategies for data management, quality transformation, and safety enhancements. Veeva emphasizes industry collaboration to drive innovation in the life sciences sector.

Veeva Systems (NYSE: VEEV) announces its 2022 Veeva Industries Virtual Summit, scheduled for Oct. 24-27. Leaders from major companies like Unilever, Reckitt, and Estée Lauder will discuss digital strategies to boost innovation and accelerate product market entry. The event features over 15 sessions focused on leveraging digital systems in quality, regulatory, and advertising claims.

Experts will explore how these technologies enhance supply chain resilience and foster sustainable product development. Attendance is complimentary for Veeva customers and qualified professionals.

Veeva Systems (NYSE: VEEV) has announced that INCOG BioPharma Services has implemented the Veeva Vault Quality Suite at its new 90,000-square-foot facility in Pleasanton, CA. This suite facilitates seamless collaboration and transparency in manufacturing processes, enhancing operational efficiency and compliance. With the integration of various Veeva applications, INCOG aims to unify quality functions and streamline workflows, ultimately accelerating the delivery of injectable drugs. This partnership emphasizes the commitment to advancing quality management in the life sciences sector.

Veeva Systems (NYSE: VEEV) reported strong fiscal Q2 2023 results with total revenues of $534.2 million, a 17% increase year-over-year. Subscription services revenues also rose by 17% to $428.6 million. However, net income fell 17% to $90.6 million, resulting in a diluted net income per share of $0.56. Non-GAAP metrics showed improvements, with non-GAAP net income increasing 9% to $166.2 million. For fiscal Q3, Veeva forecasts revenues between $545 million and $547 million.

Veeva Systems announces that Veranex is utilizing Veeva Vault CDMS to enhance clinical data management, streamlining study builds and enabling mid-study amendments without downtime. This partnership allows Veranex to build complex studies rapidly and improve collaboration with clients, thus accelerating high-quality trial execution. As a comprehensive service provider in the medical technology sector, Veranex benefits from Veeva's innovative technology to address the complexities of clinical studies efficiently.